AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 19 analysts
Fundamentals
Fundamentals institutional score is 91 using growth durability 91.0.
Valuation
Valuation institutional score is 53 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 54 using mean target upside 13.1%; dispersion penalty 17.0; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 63 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 7 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals provide support, while valuation and analyst consensus remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 5.4% above historical median. Valuation is declining — currently in the overvalued zone (z-score: +0.57). Confidence: 89%.
Live forward EPS implies next-12-month EPS of ₹70.39. Applying the stock's normalized valuation corridor produces a fair range of ₹3,057.04 to ₹3,561.03, with base value near ₹3,324.52 (+36.4% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹70.39
Forward P/E
34.6x
Base Fair Value
₹3,324.52
Fair Range
₹3,057.04 - ₹3,561.03
Upside To Base
+36.4%
Estimate Source
Live forward EPS
Growth Estimate
+29.6%
5Y Average
46.06
Current
49.76
Overvalued
50.59
Undervalued
43.43
5Y Average
24.99
Current
27.00
Overvalued
27.30
Undervalued
22.99
5Y Average
6.32
Current
6.83
Overvalued
7.27
Undervalued
5.38
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
CIPLA LTD CIPLAPharmaceuticals | +3.5% | 12.0% | 35.0x Undervalued | -24% vs avg | -3.8% |
TORRENT PHARMACEUTICALS L TORNTPHARMPharmaceuticals | +54.8% | 13.9% | 78.1x Premium | +70% vs avg | +35.8% |
LUPIN LIMITED LUPINPharmaceuticals | +32.0% | 18.5% | 19.4x Undervalued | -58% vs avg | +18.3% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.7x Undervalued | -22% vs avg | +9.4% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 38.8x Undervalued | -16% vs avg | -15.4% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.5x Undervalued | -16% vs avg | +30.0% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 91.9x Premium | +100% vs avg | +123.1% |
DR. REDDY S LABORATORIES DRREDDYPharmaceuticals | -5.6% | 10.0% | 30.7x Undervalued | -33% vs avg | -5.0% |
MANKIND PHARMA LIMITED trades in line with peers (49.5x vs avg 46.0x), reflecting a fair valuation within the Pharmaceuticals cohort. Peers include CIPLA LTD, TORRENT PHARMACEUTICALS L, LUPIN LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹2.96K CrJun 2026Latest net profit
₹558 CrJun 2026Latest EPS
₹13.52Jun 2026Net margin
31.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,092 | 2,260 | 2,209 | 2,007 | 2,413 | 2,544 | 2,414 | 2,119 | 2,570 | 2,609 | 2,633 | 2,582 | 2,964 |
| Expenses + | 1,594 | 1,662 | 1,636 | 1,482 | 1,837 | 1,781 | 1,668 | 1,778 | 1,885 | 1,916 | 1,854 | 1,663 | 2,035 |
| Operating Profit | 498 | 598 | 573 | 526 | 576 | 763 | 746 | 342 | 685 | 693 | 778 | 919 | 929 |
| OPM % | 24% | 26% | 26% | 26% | 24% | 30% | 31% | 16% | 27% | 27% | 30% | 36% | 31% |
| Other Income + | 87 | 84 | 92 | 109 | 125 | 139 | 70 | 220 | 65 | 78 | -27 | 104 | 34 |
| Interest | 2 | 4 | 4 | 4 | 7 | 3 | 200 | 162 | 149 | 147 | 138 | 125 | 95 |
| Depreciation | 69 | 77 | 90 | 87 | 91 | 90 | 91 | 115 | 105 | 99 | 108 | 109 | 111 |
| Profit before tax | 514 | 601 | 571 | 543 | 603 | 810 | 525 | 284 | 496 | 525 | 505 | 788 | 757 |
| Tax % | 20% | 21% | 15% | 14% | 16% | 20% | 22% | 16% | 16% | 13% | 11% | 9% | 26% |
| Net Profit + | 409 | 473 | 487 | 468 | 506 | 645 | 412 | 238 | 415 | 459 | 449 | 714 | 558 |
| EPS in Rs | 10.22 | 11.80 | 12.16 | 11.68 | 12.62 | 16.11 | 9.99 | 5.77 | 10.06 | 11.12 | 10.87 | 17.29 | 13.52 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Board Meeting Outcome for For Appointment Of An Additional Director Designated As Non-Executive Independent Director